Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta
Dominique Roulot(Hôpital Avicenne), Sophie Hillaire, Frédéric Le Gal(Sorbonne Université), Cécile Goujard, Jérôme Gournay(Radboud University Nijmegen), Ségolène Brichler(Inserm), Zahia BenAbdesselam(Hôpital Avicenne), Julie Bottero, Paul Calès(Centre Hospitalier Universitaire d'Angers), Victor de Lédinghen(Université de Bordeaux), Ghassan Riachi(Hôpital Charles-Nicolle), Olivier Chazouillères, Dominique Salmon(Assistance Publique – Hôpitaux de Paris), V. Loustaud‐Ratti(Hôpital Dupuytren), H Labadie(Hôpital Cochin), Pierre Nahon(Inserm), Xavier Causse, Richard Layese(Assistance Publique – Hôpitaux de Paris), Caroline Scholtès(Université Claude Bernard Lyon 1), Fabien Zoulim(Université Claude Bernard Lyon 1), Vincent Thibault, Éric Nguyen-Khac(Université de Lille), Sophie Métivier, Nathalie Ganne‐Carrié(Inserm), Isabelle Rosa, Emmanuel Gordien(Inserm), Christophe Hézode(Inserm), Bruno Roche(Hôpital Paul-Brousse), Philippe Mathurin(Université de Lille), Dominique Guyader(Inserm), Sylvie Naveau, Hélène Fontaine(Hôpital Cochin), Thierry Poynard, Françoise Roudot‐Thoraval(Centre Hospitalier Universitaire Henri-Mondor), François Habersetzer(Inserm), Laurent Alric, Roland Landman, Jean‐François Cadranel, Corinne Castelnau(Inserm), Caroline Lascoux‐Combe(Université Claude Bernard Lyon 1), Jean‐Didier Grangé, Pierre Sellier(Inserm)
Cited by 151
Related Papers
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids
|Hepatology|2007|721
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
|Gastroenterology|2009|693
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
|New England Journal of Medicine|2018|605